Media Center

Keep up with Kanexthal news and downloads for extra support!

Guangzhou Nansha Delivers “One‑Time Cure” Cell and Gene Therapies for Transfusion‑Dependent Thalassemia Patients

Nansha Hospital in Guangzhou has rapidly treated 13 β‑thalassemia patients with advanced stem cell and gene‑based therapies, reporting multiple transfusion‑free “lifelong cure” discharges under China’s pioneering Greater Bay Area policy pilot for innovative cell and gene treatments. Read more here.

Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.

A non-randomized, open-label, single-dose study that aims to evaluate the safety and efficacy of treatment involving lentiviral vector encoding βA-T87Q-globin gene transduced autologous hematopoietic stem cells in subjects with transfusion-dependent β-thalassemia. Read more here.

Β-Thalassemia Treatment with KL003 Cell Injection

A Phase 1/2 study to assess KL003 Cell Injection in up to 41 participants with transfusion-dependent β-thalassemia (TDT) who are ≥3 and ≤35 years of age. Read more here.

Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

A non-randomized, open-label, single-dose study that aims to evaluate the safety and efficacy of the treatment with lentiviral vector encoding βA-T87Q-globin gene transduced autologous hematopoietic stem cells transfusion in subjects with transfusion-dependent β-thalassemia. Read more here.

4998 Gene Therapy of Transfusion-Dependent β-Thalassemia Patients with Quick Engraftment of Reinfused Hematopoietic Stem Cells: An Investigator-Initiated Trial of KL003

A study examining autologous hematopoietic stem cell (HSC)-based gene therapy on an intensive level, reporting results regarding blood transfusions no longer needed from median day 14 after treatment, the longest duration without blood transfusion being 18 months, and the median engraftment time for neutrophils and platelets. Read more here.

4961 Deciphering Hematopoietic Reconstitution Dynamics of Lentiviral Vector HBBT87Q-Engineered Hematopoietic Stem Cells Gene Therapy for β-Thalassemia Patients

This ASH 2024 study reports that three transfusion‑dependent β‑thalassemia patients treated with the autologous lentiviral gene therapy KL003 (HBB T87Q) all achieved sustained transfusion independence at a median 11‑month follow‑up, with successful and durable engraftment of gene‑engineered hematopoietic stem cells across blood lineages. Read more here.

Kanglin Biotechnology Announces $20 Million Series A Financing to Advance the Development of Gene Therapies

With the successful completion of a Series A financing of $20 million, more financial resources will be allocated to developing Kanexthal. Read more here.

Kanexthal (KL003) Recognized in Guangdong Science & Technology Program for Pioneering Gene Therapy in β‑Thalassemia and Sickle Cell Disease

Guangdong’s Department of Science and Technology highlights Kanexthal as an innovative lentiviral gene therapy delivering a functional β‑globin gene for one‑time treatment of transfusion‑dependent β‑thalassemia. Read more here.

Nansha Hospital Emerges as China’s Leading Cell and Gene Therapy Hub, Accelerating Thalassemia Gene Treatment from Lab to Bedside

This South Daily feature highlights how Guangzhou Nansha’s pioneering cell and gene therapy policies and platforms have enabled rapid clinical translation, including the nation’s first transfusion‑dependent β‑thalassemia gene therapy program at Nansha Hospital with 29 patients treated and 27 already discharged. Read more here.

Nansha Hospital's Cell and Gene Therapy Program Aids 27 Thalassemia Patients Back to a Normal Life

This NF News piece reports that Guangzhou First People’s Hospital Nansha Hospital has now treated 29 transfusion‑dependent β‑thalassemia patients with cell and gene therapy, with 27 already discharged. Read more here.

Available downloads

Patient Screening Information

Media Center

​​​

Keep up with Kanexthal news and downloads for extra support!

​​

​​​Guangzhou Nansha Delivers “One‑Time Cure” Cell and Gene Therapies for Transfusion‑Dependent Thalassemia Patients

​​

​​​

Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.

​​​

A non-randomized, open-label, single-dose study that aims to evaluate the safety and efficacy of treatment involving lentiviral vector encoding βA-T87Q-globin gene transduced autologous hematopoietic stem cells in subjects with transfusion-dependent β-thalassemia. Read more here.

​​

Β-Thalassemia Treatment with KL003 Cell Injection

​​​

A Phase 1/2 study to assess KL003 Cell Injection in up to 41 participants with transfusion-dependent β-thalassemia (TDT) who are ≥3 and ≤35 years of age. Read more here.​​

Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

​​​

A non-randomized, open-label, single-dose study that aims to evaluate the safety and efficacy of the treatment with lentiviral vector encoding βA-T87Q-globin gene transduced autologous hematopoietic stem cells transfusion in subjects with transfusion-dependent β-thalassemia. Read more here.

4998 Gene Therapy of Transfusion-Dependent β-Thalassemia Patients with Quick Engraftment of Reinfused Hematopoietic Stem Cells: An Investigator-Initiated Trial of KL003

​​​

4961 Deciphering Hematopoietic Reconstitution Dynamics of Lentiviral Vector HBBT87Q-Engineered Hematopoietic Stem Cells Gene Therapy for β-Thalassemia Patients

​​​

Kanglin Biotechnology Announces $20 Million Series A Financing to Advance the Development of Gene Therapies

​​​

With the successful completion of a Series A financing of $20 million, more financial resources will be allocated to developing Kanexthal. Read more here.

Kanexthal (KL003) Recognized in Guangdong Science & Technology Program for Pioneering Gene Therapy in β‑Thalassemia and Sickle Cell Disease

​​​

Guangdong’s Department of Science and Technology highlights Kanexthal as an innovative lentiviral gene therapy delivering a functional β‑globin gene for one‑time treatment of transfusion‑dependent β‑thalassemia. Read more here.

Nansha Hospital Emerges as China’s Leading Cell and Gene Therapy Hub, Accelerating Thalassemia Gene Treatment from Lab to Bedside

​​​​

Nansha Hospital's Cell and Gene Therapy Program Aids 27 Thalassemia Patients Back to a Normal Life

​​​​​

This NF News piece reports that Guangzhou First People’s Hospital Nansha Hospital has now treated 29 transfusion‑dependent β‑thalassemia patients with cell and gene therapy, with 27 already discharged. Read more here.

Available downloads

Guangzhou Nansha Delivers “One‑Time Cure” Cell and Gene Therapies for Transfusion‑Dependent Thalassemia Patients

A Phase 1/2 study to assess KL003 Cell Injection in up to 41 participants with transfusion-dependent β-thalassemia (TDT) who are ≥3 and ≤35 years of age. Read more here.